Baxter reveals expansion plans for its Germany facility
The firm said it is adding another 1,750m² space to the facility, which continues to grow and aims to meet the needs of growing clients for cytotoxic manufacturing.
The US Food and Drug Administration (FDA) has declined to approve Unicycive Therapeutics’ resubmitted new drug application (NDA) for oxylanthanum carbonate (OLC) to treat hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis.
GCLP status indicates that the operation standards of the contract research division are compliant with the British Association of Research Quality Assurance standards. Epistem contract research division co-founder
Precision’s next-generation genome engineering technologies, collectively known as the Directed Nuclease Editor or DNE, aids in making the tools and resulting cells possible. Precision chief scientific officer and
The patent entitled, ‘Systems, Methods and Devices for Frozen Sample Distribution’, covers the company’s core technology, which provides efficient access to the highly valuable frozen biosamples for important
AbCheck’s commercial multi antibody discovery platforms include AbSieve, which combines the company’s proprietary phage and yeast display technologies. Under the deal, AbCheck will use AbSieve antibody discovery platform